Avita Medical Reports Third Quarter- and Nine-Month Financial Results

May 2011
Biomedical Market Newsletter;5/5/2011, p112
The article reports that Avita Medical Ltd., a regenerative medicine company, has released its financial results for the 3rd quarter and nine months ending, ending March 31, 2011, in Great Britain. According to William Dolphin, chief executive officer (CEO) of Avita Medical, the sales of their ReCell Spray-On-Skin regenerative product have shown strong growth for consecutive quarters. A brief description of the company is provided, including its ReCell Spray-On-Skin product.


Related Articles

  • Skin trade: partnership seeks greater understanding of wound healing device.  // Engineer (Online Edition);8/20/2015, p1 

    The article reports on the partnership of Huddersfield University in England and regenerative medicine company Avita Medical Ltd. to explore the mechanism of Regenerative Epithelial Suspension (RES) to better understand its ability to treat cutaneous anomalies including burns.

  • Study Demonstrates That Avita Medical's ReCell(r) Spray-On Skin(tm) "Has Potentially Broad Application to the Healing of Acute and Chronic Wounds".  // Biomedical Market Newsletter;5/7/2011, p92 

    The article evaluates ReCell® Spray-On Skin™, from Avita Medical Ltd., a regenerative medicine that been proven with potential broad application in treating acute and chronic wounds.

  • Avita Medical Expands Sales and Marketing Operations in Europe.  // Biomedical Market Newsletter;5/7/2011, p390 

    The article reports on the move of the regenerative medicine company Avita Medical Ltd. to expand its sales and marketing operations in Europe. It mentions that the company had aimed to work closely with highly regarded surgeons in Russia, the Netherlands and Portugal to develop a group of key...

  • AVITA GETS AU$2M FROM US MILITARY TO SPEED DEVICE APPROVAL.  // Worldwide Biotech;Jul2009, Vol. 21 Issue 7, p2 

    The article reports that $1.45 million have been given by the U.S. Armed Forces Institute of Regenerative Medicine (AFIRM) to Avita Medical Ltd. The money will be used to speed up the approval of the ReCell Autologous Cell Harvesting device of Avita in the U.S. It is noted that the device will...

  • Avita Medical Reports Additional Market Acceptance of its ReCell(r) Spray-On-Skin(tm).  // Biomedical Market Newsletter;6/19/2011, p1039 

    The article reports on the introduction of ReCell Spray-On-Skin by Avita Medical Ltd. It says that ReCell was presented at the Cosmedica 2011 Congress for Aesthetic & Surgical Medicine in Bochum, Germany. It cites that a workshop procedure using ReCell with a carbon dioxide fractional laser was...

  • Avita Medical Sponsors Inaugural Skin Regeneration Symposium.  // Biomedical Market Newsletter;4/1/2012, Vol. 21, p1 

    The article provides information on the inaugural Skin Regeneration Symposium sponsored by Avita Medical Ltd. that was held from March 23-24, 2012 in Rome, Italy. The symposium was aimed for expert users of ReCell (®) Spray-On Skin (®) to present their research and findings in skin...

  • Avita Medical Initiates Trading on US OTCQX.  // Biomedical Market Newsletter;4/1/2012, Vol. 21, p1 

    The article reports on the trading of the American depositary receipts initiated by the regenerative medical company Avita Medical Ltd. on the OTCQX Markets Group Inc. of the U.S. Trading on the OTCQX marketplace provides helps the U.S. investors of the company with a direct market for...

  • Bridge Report on CellSeed Issued: 1H FY12/11 Sales and Operating Losses in Line with Expectations, FY12/11 Estimates Remain Unchanged.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p1149 

    The article offers information on a "Bridge Report" on CellSeed Inc. released by Investment Bridge in Japan. It mentions that the report shows that the leading company in regenerative medicine has recurring losses of 584 million Japanese yen (JPY) and sales of JPY43 million in the first half of...

  • SPOTLIGHT. Hill, Joanna // Australasian Biotechnology;Feb2011, Vol. 21 Issue 1, p36 

    The article presents the financial portfolio of biotechnology companies listed in the Australia Securities Exchange (ASX). It presents the principal activity of CBio Ltd. was which listed in February 2010. It relates the market capitalization of Avita Medical Ltd. which was listed in August...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics